Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry
Riccardo Campi(University of Florence), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), J. Rubio‐Briones, Tobias Klatte(Helios Hospital Bad Saarow), Selçuk Erdem(European Association of Urology), Estefanía Linares(Hospital Universitario La Paz), Umberto Capitanio(Vita-Salute San Raffaele University), Michele Marchioni(University of Chieti-Pescara), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Riccardo Autorino(Rush University Medical Center), M. Kriegmair(Urologische Klinik München), Thomas Amiel(Technical University of Munich), Georgi Guruli(VCU Massey Comprehensive Cancer Center), Siska Van Bruwaene(AZ Groeninge), Mireía Musquera(Surgical Specialties (Canada)), C. Palumbo, Alessandro Antonelli(University of Verona), Nicola Pavan(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Fady Ghali(University of California San Diego), F. Porpiglia(Ospedale San Luigi Gonzaga), Ithaar Derweesh(Rush University Medical Center), Eduard Roussel, M. Heck(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Vital Hevia(Hospital Universitario Ramón y Cajal)
Cited by 1
Related Papers
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Supine Valdivia and modified lithotomy position for simultaneous anterograde and retrograde endourological access
|British Journal of Urology|2007|288
Urology practice during the COVID-19 pandemic
|Minerva Urologica e Nefrologica|2020|256
NIFEDIPINE VERSUS TAMSULOSIN FOR THE MANAGEMENT OF LOWER URETERAL STONES
|The Journal of Urology|2004|242